WY-14643 (Pirinixic Acid): Selective PPARα Agonist for Metabolic Research

Executive Summary: WY-14643 (Pirinixic Acid) is a highly potent and selective agonist of peroxisome proliferator-activated receptor alpha (PPARα) with an IC₅₀ value of 10.11 µM for human PPARα, enabling precise lipid metabolism regulation in vitro and in vivo (APExBIO). Dual PPARα/γ agonist activity is achieved via aliphatic α-substitution, expanding its utility in metabolic disorder research (Pepstatina.com). Animal studies confirm that WY-14643 significantly reduces plasma glucose, triglycerides, and visceral fat, while improving insulin sensitivity without weight gain (Alarelinacetate.com). WY-14643 also downregulates TNF-α–induced VCAM-1 expression in endothelial cells, demonstrating robust anti-inflammatory effects. Its role in liver regeneration via YAP-TEAD mediation provides mechanistic insight for regenerative research (see Evidence & Benchmarks).

Biological Rationale

PPARα is a nuclear receptor that regulates genes involved in fatty acid oxidation, lipid transport, and inflammation. Activation of PPARα is fundamental to the control of hepatic and systemic lipid homeostasis (APExBIO). Dysregulation of PPAR signaling is implicated in metabolic syndrome, type 2 diabetes, steatohepatitis, and cardiovascular disease. WY-14643 (Pirinixic Acid), by selectively activating PPARα, allows for targeted manipulation of these pathways in experimental settings (Related Article), extending previous reports by benchmarking its dual agonist potential in addition to its canonical selectivity.

Mechanism of Action of WY-14643 (Pirinixic Acid)

WY-14643 binds to the ligand-binding domain of PPARα, inducing conformational changes that recruit transcriptional co-activators. This leads to upregulation of genes involved in β-oxidation of fatty acids, peroxisomal proliferation, and anti-inflammatory responses. The compound’s IC₅₀ for human PPARα is 10.11 µM, demonstrating high potency (APExBIO). Aliphatic α-substitution on WY-14643 enhances dual PPARα/γ activation, with balanced effects in the low micromolar range. In endothelial cells, WY-14643 inhibits TNF-α–induced VCAM-1 upregulation and monocyte adhesion, indicating direct anti-inflammatory action (Alarelinacetate.com), extending the mechanistic coverage beyond lipid metabolism alone.

Evidence & Benchmarks

• WY-14643 (100 mg/kg/day, i.p.) induces significant hepatomegaly and promotes liver regeneration in C57BL/6 mice via YAP-TEAD pathway activation (Golgi-mturquoise2.com). This article extends prior mechanistic reports by directly linking YAP-TEAD mediation to PPARα agonism.
• In high fat-fed rats, oral WY-14643 (3 mg/kg/day, 2 weeks) lowers plasma glucose, triglycerides, leptin, muscle triglycerides, and long-chain acyl-CoAs, and enhances whole-body insulin sensitivity without body weight gain (Alarelinacetate.com).
• WY-14643 pretreatment (250 μM) significantly downregulates TNF-α–induced VCAM-1 expression and reduces monocyte adhesion in endothelial cell cultures (Pepstatina.com).
• Compound is insoluble in water; solubility in DMSO ≥16.2 mg/mL, in ethanol ≥48.8 mg/mL (with sonication); stable at -20°C for short-term solution use (APExBIO).
• In Pparα-deficient mice, WY-14643 fails to induce hepatomegaly or regenerative effects, proving the requirement for functional PPARα (Golgi-mturquoise2.com).

Applications, Limits & Misconceptions

WY-14643 is widely used for:

• Modulating lipid metabolism and fatty acid oxidation in hepatocytes and animal models.
• Investigating PPARα and PPARγ signaling in metabolic syndrome, NASH, and atherosclerosis models.
• Evaluating anti-inflammatory mechanisms in cardiovascular and endothelial contexts, especially via TNF-α pathways.
• Probing liver regeneration and cell proliferation via YAP-TEAD–PPARα crosstalk.

This article clarifies and extends the analysis of prior reviews by providing stepwise, quantitative benchmarks and highlighting APExBIO’s product reliability in translational workflows.

Common Pitfalls or Misconceptions

• WY-14643 is not effective in PPARα-knockout or hepatocyte-specific PPARα-deficient models; observed effects are strictly PPARα-dependent.
• It is not suitable for aqueous formulations due to its insolubility in water; DMSO or ethanol (with sonication) are required for stock solutions.
• WY-14643 is not intended for diagnostic or clinical therapeutic use; it is strictly supplied for scientific research purposes.
• Dual PPARα/γ activity is only evident with specific α-substitution; the parent compound remains predominantly PPARα-selective.
• Prolonged storage of working solutions at room temperature leads to compound degradation; always store at -20°C and use within recommended timeframes.

Workflow Integration & Parameters

WY-14643 is supplied as a solid and must be dissolved in DMSO (≥16.2 mg/mL) or ethanol (≥48.8 mg/mL with ultrasonication) before use. For in vitro studies, 250 μM is effective for anti-inflammatory assays in endothelial cells. For in vivo, oral dosing of 3 mg/kg/day (rats) or i.p. injection of 100 mg/kg/day (mice) are standard for metabolic and regeneration studies. Solutions should be freshly prepared or stored at -20°C short-term. Always reference the product page for updated protocols. APExBIO ensures batch-to-batch consistency, supporting reproducible research outputs.

Conclusion & Outlook

WY-14643 (Pirinixic Acid) remains a benchmark tool for selective PPARα agonism in metabolic, inflammatory, and regenerative medicine research. Its atomic mechanism, validated in diverse models, supports robust delineation of PPAR signaling. With reproducible results across metabolic endpoints and anti-inflammatory effects, it underpins ongoing work in translational science. For in-depth mechanistic updates and strategic deployment guidance, see the comprehensive review on WY-14643 mechanistic mastery, which this article extends by providing new evidence from recent in vivo models. Always consult the latest data and product documentation from APExBIO for optimal experimental design.